Merck Inc announces phase III KEYNOTE-826 trial met dual primary endpoints of overall survival and progression-free survival in patients with persistent, recurrent or metastatic cervical cancer
Merck Inc., announced that the pivotal Phase III KEYNOTE-826 trial investigating Keytruda, Merck’s anti-PD-1 therapy, in combination with platinum-based chemotherapy (paclitaxel plus cisplatin or paclitaxel plus carboplatin) with… read more.
